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Abstract
Increasing evidence suggests that after the first
pro-inflammatory hours, sepsis is characterized by the
occurrence of severe immunosuppression. Several
mechanisms have been reported to participate in
sepsis-induced immune alterations affecting both
innate and adaptive immunity. Of these, the concept
of ‘cell exhaustion’ has gained a lot of interest
because some parallels can be drawn with the cancer
field in which immunostimulation approaches
through blocking immune checkpoints currently
obtain remarkable success. Herein, perspectives
regarding co-inhibitory receptors’ contribution to
lymphocyte exhaustion in sepsis will be discussed in
the context of a recently published study investigating
the potential of PD-1 molecule expression (i.e. PD-1
on lymphocytes, PD-L1 on monocytes) to predict
mortality in septic shock patients.
The work by Shao et al. [1] provides further insights re-
garding the potential of Programmed Death-1 (PD-1)-re-
lated molecule expression to predict mortality in septic
shock patients. These immune checkpoint molecules
constitute a system of negative regulators involved in
controlling T-cell responses. Co-ligation of TCR with
PD-1 molecules induces an inhibitory signal in T cells
characterized by cell cycle arrest, inability to proliferate
and reduced cytokine synthesis (IFN-γ and/or IL-2).
This system is composed of PD-1 (CD279) and its two
ligands, PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC,
CD273). Viruses and tumour cells take advantage of this
pathway to escape the host’s immune defences. In sepsis,
pioneering work by Pr Ayala’s group published in 2009
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reported that PD-1 knockout mice exhibited greater cap-
acity to clear bacteria and lower mortality after experi-
mental sepsis [2]. Since this report, the implication of
PD-1 molecules in sepsis-induced immunosuppression
has been largely demonstrated both in experimental and
clinical studies.
In septic mice, administration of anti-PD1/anti-PD-L1
antibodies enhanced bacterial clearance by preventing
lymphocyte depletion and alterations [3, 4]. In a two-hit
model nicely mimicking the occurrence of nosocomial
infection (sepsis + secondary fungal infection), those
antibodies significantly improved survival [4]. In septic
patients, several groups reported increased PD-1 expres-
sion on lymphocytes and monocytes [5–8]. Depending
on studies, this overexpression was regularly observed to
be associated with increased risk of nosocomial infections
and mortality. Of note, other co-inhibitory receptors
(BTLA, CTLA-4, TIM-3, LAG-3) are also overexpressed
in sepsis. Along with altered functional responses (prolif-
eration/IFN-γ production), this depicts a full picture of
sepsis-induced lymphocyte exhaustion. Importantly, those
results obtained in circulating blood cells were confirmed
locally in organs (lung and spleen), illustrating this overex-
pression is a severe and profound mechanism [8]. The
magnitude of this immunosuppression is also exemplified
by patients’ difficulty to fight the primary bacterial in-
fection, decreased resistance to secondary nosocomial
infections and reactivation of viral infections [9].
Noteworthy, the implication of PD-1 molecules was re-
cently reported in Ebola disease pathophysiology (which
shares many clinical similarities with septic shock). While
every Ebola-infected patient showed massive T-cell activa-
tion irrespective of outcome, the increased expression of
these immune checkpoint molecules marked fatal evolu-
tion in some patients and correlated with high viraemia
[10]. The authors hypothesized that these inhibitory
molecules inhibit T-cell functions leading to poor viral
clearance—a similar consequence to those observed
during sepsis-induced immunosuppression.
Shao et al.’s study [1] agrees with this body of literature
and provides two important novel aspects. Firstly, to our
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knowledge, this study represents the first description of a
PD1 molecule, namely PD-L1, as an independent pre-
dictor of mortality in a multivariate analysis. Indeed, a
combined score including the SAPS II score and PD-L1
expression provided good prognostic performances with
an area under the curve in ROC analysis of 0.88. This
illustrates the weight of initial severity and immunosup-
pression in sepsis. Secondly, it highlights the importance
of monocytes in the PD-1 system and more broadly in
sepsis-induced immune alterations. Indeed, the best result
for predicting mortality is not obtained with PD-1-related
molecule expressions on lymphocytes but rather with PD-
L1 expression on monocytes. This again places monocytes
at the centre of the pathophysiological game. Correlations
between increased monocyte PD-L1 expression and de-
creased expression of HLA-DR or in-vitro TNF release—-
both typical markers of monocyte alterations—would thus
have been interesting to support this hypothesis. In line
with this, Shindo et al. [11] reported that anti-PD-1 anti-
body treatment had a positive effect on MHC class II mol-
ecule expression on macrophages and dendritic cells.
Thus, the real importance of the PD-1 system on myeloid
cells deserves further investigation.
Importantly, sepsis-induced impaired immune func-
tion is reversible and it remains possible to rejuvenate
exhausted lymphocytes [12]. Among molecules able to
participate in battling sepsis-induced immunosuppression,
anti-PD-1/anti-PD-L1 antibodies thus appear as plausible
candidates. In septic patients’ cells, ex-vivo blockade of the
PD-1 system restored immune functions [13] while these
agents currently provide excellent results in cancer ther-
apy, in which they boost immune functions in adjunction
to classical therapies. Nevertheless, this approach deserves
to be envisaged with caution. Indeed, PD-1-related mole-
cules are also involved in the tolerance phenomenon and
belong to the normal process of T-cell differentiation/mat-
uration and activation. In other words, PD-1 expression is
not always a sign of T-cell alteration and does not neces-
sarily mark reduced T-cell functions and exhaustion [14].
By unbalancing the immune system, immune checkpoint
blockade thus favours the development of various auto-
immune manifestations [15]. As a consequence, one im-
portant issue if we are to give anti-PD-L1 therapy to septic
patients is to identify the right patient that could benefit
from such therapy because it is unlikely, due to well-
established heterogeneity of septic patients, that blocking
a given immune checkpoint will be a magic bullet for all.
Thus, robust standardized tools for patients’ stratification
are highly desirable. In that sense, the work of Shao et al.
[1] contributes to a better knowledge of PD-L1 expression
as a potential biomarker.
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